This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Medication Adherence Therapy for Opioid Abusing Pain Patients

This study has been completed.
Sponsor:
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00249587
First received: November 3, 2005
Last updated: January 9, 2017
Last verified: September 2008
November 3, 2005
January 9, 2017
September 2000
September 2005   (Final data collection date for primary outcome measure)
  • Medication compliance and unauthorized drug use [ Time Frame: 24 weeks ]
  • Changes in pain severity and functioning [ Time Frame: 24 weeks ]
  • Medication compliance and unauthorized drug use
  • Changes in pain severity and functioning
Complete list of historical versions of study NCT00249587 on ClinicalTrials.gov Archive Site
  • Satisfaction with services [ Time Frame: 12 weeks ]
  • Therapeutic alliance [ Time Frame: 12 weeks ]
  • Satisfaction with services
  • Therapeutic alliance
Not Provided
Not Provided
 
Medication Adherence Therapy for Opioid Abusing Pain Patients
Medication Adherence Therapy for Opioid Abusing Pain Patients
The purpose of this study is to develop and pilot test a combined behavioral and pharmacological intervention designed to decrease pain, functional interference, and drug abuse while increasing medication adherence.
Project Pain is a Stage I behavioral therapies development project aimed at developing and pilot testing a novel intervention for patients with chronic non-malignant pain who have experienced difficulty managing prescribed opioids. The goals of the study are to: (1) develop the intervention and training materials; (2) develop therapist adherence and competence scales; (3) train therapists to deliver the intervention per the treatment protocol; and (4) pilot the intervention to assess its feasibility, acceptability and promise. The goals of the intervention are to: (1) improve adherence to prescribed opioids; (2) decrease the severity of patients' pain; and (3) improve patients' functioning and quality of life .
Interventional
Phase 1
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Pain
  • Chronic Disease
  • Prescription Opioid Abuse
Drug: Methadone
dosed to effect, every six hours
  • Experimental: 1
    Methadone plus behavioral counseling consisting of adherence, self-monitoring, and motivational interviewing
    Intervention: Drug: Methadone
  • Active Comparator: 2
    Methadone plus behavioral counseling consisting of adherence
    Intervention: Drug: Methadone
  • Haller, D.L., Heckman-Stone, C. Ingersoll, K.: Drug and Alcohol Dependence. 2002; 66, S73, #270
  • Wunsch, M.J., Cropsey, K.L., Haller, D.L.: Drug and Alcohol Dependence. 2002; 66, S198, #747
  • Fox, S.A., Haller, D.L., Weaver, M.F.: Proceedings from CPDD 2003 Annual Meeting, Bal Harbour, Florida. #197
  • Paper presented at the American Academy of Addiction Psychiatry, December, 2004

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
36
September 2005
September 2005   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Uninterrupted pain of at least 6 months duration
  • Pain is continuous, rather than intermittent
  • Pain in the severe range (VAS = 7-10) while medicated
  • Poor response to non-pharmacological interventions for pain (if appropriate)
  • One or more of the following pain diagnoses: (a) back/neck pain; (b) myofacial pain; (c) neuropathic pain (e.g., diabetic or AIDS neuropathy, Complex regional pain syndrome); (d) arthritic pain; (e) MS; or (f) sickle cell (must meet chronicity criteria)
  • Evidence of tolerance/physiological dependence on opioid analgesics
  • Current opioid use disorder (DSM-IV criteria)
  • Continuous use of opioid analgesics for a minimum of 6 months prior to referral. [Note: This is consistent with minimum 6-month requirement for diagnosis of chronic pain].
  • Minimum of 2 signs/symptoms of medication mismanagement identified by the Referring MD (PROBLEMS WITH PAIN MEDS checklist)

Exclusion Criteria:

  • Please contact site regarding exclusion criteria for this study.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00249587
NIDA-13169-1
R01-13169-1
No
Not Provided
Not Provided
Not Provided
Deborah Haller, Ph.D., St. Luke's-Roosevelt Hospital Center
National Institute on Drug Abuse (NIDA)
Not Provided
Principal Investigator: Deborah Haller St. Luke's Roosevelt Hosp Cntr (New York)
National Institute on Drug Abuse (NIDA)
September 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP